Skip to main content
ARECOR THERAPEUTICS PLC logo

ARECOR THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AREC ISIN · GB00BMWLM973 LEI · 98450093D12I3A8DDD58 IL Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2023-08-10 Report Publication Anno…
Country GB United Kingdom
Listing IL AREC

About ARECOR THERAPEUTICS PLC

https://arecor.com/

Arecor Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing enhanced therapeutic medicines. The company utilizes its proprietary Arestat® technology platform, a formulation science designed to improve the properties of proteins and peptides, enabling superior drug product profiles. Arecor's business model involves two approaches: developing an internal portfolio of proprietary products and partnering with pharmaceutical and medtech companies to enhance their therapeutic offerings. The company's in-house development pipeline is primarily focused on advancing treatments for diabetes and other cardiometabolic diseases, including next-generation insulin candidates.

Recent filings

Filing Released Lang Actions
Notice of Interim Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3546 characters) released via RNS (RNS Number : 8550I) from Arecor Therapeutics PLC. The title is "NOTICE OF INTERIM RESULTS" and it explicitly states that the company "will announce its Interim Results for the six months ended 30 June 2023 on Thursday 14 September 2023." This is not the actual Interim Report (IR) itself, but an announcement about when the report will be published. According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA).
2023-08-10 English
Arecor Business Update
Regulatory Filings Classification · 98% confidence The document is identified by the header "RNS Number : 5821G" and contains a date (20 July 2023) and a business update titled "BUSINESS UPDATE". It explicitly mentions that the company "today provides a business update and announces that its interim results for the six months ended 30 June 2023 will be issued in mid-September." The content is a general operational and pipeline update, not the full interim financial report itself. The presence of the RNS header and the nature of the announcement (a general update with forward-looking statements and pipeline progress) strongly suggests a regulatory news service announcement. Since it is not a specific report like 10-K, ER, or IR, and it is a formal announcement distributed via RNS, the most appropriate classification is Regulatory Filings (RNS), which serves as a general category for such market communications.
2023-07-20 English
Additional Agreement with Leading Biopharma
M&A Activity Classification · 99% confidence The document is a short announcement released via RNS (Regulatory News Service) on July 5, 2023. It details a new agreement between Arecor Therapeutics plc and a biopharmaceutical company regarding a biosimilar product development. The text is brief, contains contact information, and concludes with standard RNS disclaimers and an RNS number. This structure strongly indicates a general regulatory announcement that doesn't fit the specific categories like ER, IR, or CAP. Since it is a general regulatory update disseminated through the official news service (RNS), and it is not a full report, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2023-07-05 English
Arecor granted key patents in Europe and China
Regulatory Filings Classification · 99% confidence The document begins with an RNS Number (9686D) and a date (27 June 2023), indicating it is a regulatory news service announcement from the London Stock Exchange. The content announces that Arecor has been granted key patents in Europe and China protecting its insulin products (AT278 and AT247). This type of announcement, which details specific corporate developments (like IP grants) released via an official news wire service, fits best under the general 'Regulatory Filings' category (RNS) as it is not a comprehensive report (like 10-K or IR), a specific financial event (like DIV or CAP), or a management change (MANG). Although it relates to Intellectual Property, there is no specific code for 'Patent Grant Announcement', making RNS the most appropriate general regulatory disclosure category.
2023-06-27 English
Arecor presents positive data for AT247 at ADA
Regulatory Filings Classification · 96% confidence The document is identified by the RNS Number header and the closing statement indicating it is distributed by 'Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' The content details the presentation of positive clinical trial data for a drug candidate (AT247) at a major industry meeting (ADA annual meeting). This is a specific corporate announcement regarding scientific/clinical progress, not a full financial report (10-K, IR), a formal earnings release (ER), or a proxy statement. Since it is a specific announcement distributed via the RNS system that doesn't fit perfectly into the other specialized categories (like DIV, CAP, MANG), the most appropriate general regulatory/announcement category is RNS (Regulatory Filings), which serves as a fallback for miscellaneous regulatory announcements.
2023-06-26 English
Exercise of rollover options & Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly starts with "RNS Number : 2947C" and contains language typical of regulatory news service announcements, such as updates on share issuance, admission to trading on AIM, and notification regarding total voting rights. The content details the issuance of new ordinary shares following option exercises and provides the new total number of shares for shareholder notification purposes under FCA rules. This structure strongly indicates a general regulatory announcement disseminated via the RNS system, which aligns best with the 'Regulatory Filings' category (RNS) or potentially a 'Share Issue/Capital Change' (SHA). Since the primary function here is the dissemination of a mandatory regulatory update via the RNS feed, and it includes the total voting rights denominator, RNS is the most appropriate general classification, although SHA is also relevant. Given the context of RNS dissemination and the inclusion of voting rights information, RNS is chosen as the primary type, as it covers general regulatory announcements.
2023-06-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.